GlassScriptPhysician profile
Gustavo Plasencia
NPI 1386723567
$46,365.70
in general payments reported to CMS, 2019-2025
31 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $8,772 · 2021: $11K · 2022: $9,864 · 2023: $4,900 · 2024: $9,785 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,000 · Consulting Fee: $3,535 · Food and Beverage: $3,045 · Long Term Medical Supply Or Device Loan: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,000.00 |
| Consulting Fee | $3,535.00 |
| Food and Beverage | $3,044.74 |
| Long Term Medical Supply Or Device Loan | $626.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $36,004.58 | 2019-2025 | Da Vinci Surgical System |
| Ethicon INC. | $3,535.00 | 2023 | Echelon Endopath, Echelon Flex |
| Medtronic, INC. | $2,040.36 | 2021-2024 | Sonicision |
| Ethicon US, LLC | $984.02 | 2019-2025 | Echelon Flex, Endopath |
| Integra Lifesciences Corporation | $739.71 | 2020-2024 | Acell, Integra, Integra Dermal Regeneration Template |
| Davol INC. | $655.49 | 2021-2025 | Phasix Mesh |
| Karl Storz Endoscopy-America | $540.44 | 2019-2022 | |
| Conmed Corporation | $429.79 | 2019-2024 | Airseal |
| Innocoll Pharmaceuticals Limited | $175.12 | 2021-2022 | |
| Braintree Laboratories, INC. | $161.76 | 2019-2025 | Suflave |
| Innovation Technologies INC | $134.52 | 2020 | |
| Cook Medical LLC | $125.93 | 2019 | |
| Medical Device Business Services, INC. | $124.99 | 2021 | |
| Baxter Healthcare | $122.24 | 2022 | |
| Tela Bio, INC. | $77.11 | 2024-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $74.43 | 2019 | |
| Medtronic USA, INC. | $53.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.60 | 2020-2021 | |
| Becton, Dickinson and Company | $43.17 | 2024 | Phasix Mesh |
| Allergan, INC. | $42.73 | 2019-2020 | |
| Axonics, INC. | $37.89 | 2021 | |
| Hologic Sales and Service, LLC | $32.29 | 2023 | Coolseal Generator |
| Tempus Ai, INC | $26.78 | 2025 | Xt Cdx |
| Ferring Pharmaceuticals INC. | $25.63 | 2019 | |
| Smith+Nephew, INC. | $24.03 | 2025 | Pico 14 |
| Concordia Pharmaceuticals INC. | $22.76 | 2019 | |
| Kerecis Limited | $21.16 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Shire North American Group INC | $20.87 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.79 | 2019 | |
| Olympus America INC. | $14.91 | 2024 | Single Use Electrosurgical Knife Kd-655 |
| Redhill Biopharma INC. | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Plasencia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.